Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib?
Romain Coriat, Olivier Mir, François Goldwasser, Stanislas Pol, Stanislas Chaussade – 19 September 2011